Starpharma (ASX:SPL) reports DEP HER2-lutetium shows potent anticancer effect
[videojs_hls url=’//du7x25at22z7c.cloudfront.net/328113/index_HLSv3.m3u8′ poster=’http://www.finnewsnetwork.com.au/newssystem/2021/Headlines03_360_210316.jpg’]
Starpharma (ASX:SPL) says its second radiopharmaceutical candidate, DEP HER2-lutetium, achieved potent and durable anticancer activity, with complete tumour regression, outperforming Herceptin labelled with lutetium, in a breast cancer model.
Worldwide, breast cancer is the most common cancer in women and the second most common cancer in the US.
Radiotheranostics is a rapidly developing area of cancer treatment and diagnosis, with deals and sales estimated to grow to $12–15 billion by 2030.
Recent deals include the acquisition of Endocyte by Novartis for US$2.1 billion and the acquisition of Sirtex by CDH Genetech for $1.9 billion.
Shares in Starpharma (ASX:SPL) are trading 1.1 per cent higher at $1.89.
Copyright 2021 – Finance News Network
Source: Finance News Network
